LQDA — Put-Selling Research

by ThetaLoop Research
← Back to search
Last close: 2026-04-02
Liquidia Corporation
Healthcare · $37.68
2.0
/10
Weak
How this score works →
Regime
Bullish
vs SMA200
SMA200 Distance
+33%
Above trend
Volatility
Normal
Average premiums
Momentum
Accelerating
Price direction
About Liquidia Corporation
Liquidia is a small-cap biopharma focused on pulmonary arterial hypertension treatments. No dividend, binary FDA and pipeline risk. Options liquidity is limited and spreads can be wide. Generally not practical for consistent CSP strategies due to thin markets and event-driven price action.
Drug Manufacturers - Specialty & Generic
Market Cap
$3.3B
Beta
0.46
52-Week Range Current: $37.68
$11.26 $46.67
Earnings
2026-05-07
32 days away
📊 View Full Research Track Record (All Wins AND Losses)
These free tools show market conditions and individual scores.
Our daily research goes deeper — covering option-specific data points, strike analysis, and risk metrics delivered via Telegram.
EXPLORE OUR RESEARCH — 14 DAYS FREE